BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 16995881)

  • 1. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.
    de Jong JM; Schuurhuis DH; Ioan-Facsinay A; Welling MM; Camps MG; van der Voort EI; Huizinga TW; Ossendorp F; Verbeek JS; Toes RE
    Immunology; 2006 Dec; 119(4):499-506. PubMed ID: 16995881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells.
    Guéry JC; Adorini L
    J Immunol; 1995 Jan; 154(2):536-44. PubMed ID: 7529278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
    Dembic Z; Schenck K; Bogen B
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo.
    Levin D; Constant S; Pasqualini T; Flavell R; Bottomly K
    J Immunol; 1993 Dec; 151(12):6742-50. PubMed ID: 7903097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: comparative analysis of carbohydrate structures and the antigen presenting cell.
    González-Fernández M; Carrasco-Marín E; Alvarez-Domínguez C; Outschoorn IM; Leyva-Cobián F
    Cell Immunol; 1997 Feb; 176(1):1-13. PubMed ID: 9070312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.
    Kleindienst P; Brocker T
    Immunology; 2005 Aug; 115(4):556-64. PubMed ID: 16011524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.
    Boross P; van Montfoort N; Stapels DA; van der Poel CE; Bertens C; Meeldijk J; Jansen JH; Verbeek JS; Ossendorp F; Wubbolts R; Leusen JH
    J Immunol; 2014 Dec; 193(11):5506-14. PubMed ID: 25355925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
    Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
    Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation.
    Aubin É; Proulx DP; Trépanier P; Lemieux R; Bazin R
    Clin Immunol; 2011 Dec; 141(3):273-83. PubMed ID: 21824820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
    Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
    Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo.
    de Jong JM; Schuurhuis DH; Ioan-Facsinay A; van der Voort EI; Huizinga TW; Ossendorp F; Toes RE; Verbeek JS
    Mol Immunol; 2006 May; 43(13):2045-50. PubMed ID: 16513171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
    Periasamy P; O'Neill HC
    Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wortmannin, an inhibitor of phospholipase D activation, selectively blocks major histocompatibility complex class II-restricted antigen presentation.
    Carrasco-Marín E; Alvarez-Domínguez C; Leyva-Cobián F
    Eur J Immunol; 1994 Sep; 24(9):2031-9. PubMed ID: 8088323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T/B cell interaction involved in induction of the mouse IgG2ab suppression is restricted by major histocompatibility complex class I, but not class II molecules.
    Majlessi L; Bordenave G
    Eur J Immunol; 1997 Jun; 27(6):1346-52. PubMed ID: 9209483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules.
    Brazil MI; Weiss S; Stockinger B
    Eur J Immunol; 1997 Jun; 27(6):1506-14. PubMed ID: 9209504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient T and B cell activation after neonatal induction of tolerance to MHC class II or Mls alloantigens.
    Schurmans S; Brighouse G; Kramer G; Wen L; Izui S; Merino J; Lambert PH
    J Immunol; 1991 Apr; 146(7):2152-60. PubMed ID: 1672344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid constitutive generation of a specific peptide-MHC class II complex from intact exogenous protein in immature murine dendritic cells.
    Colledge L; Bennett CL; Reay PA; Blackburn CC
    Eur J Immunol; 2002 Nov; 32(11):3246-55. PubMed ID: 12555670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin.
    Zaghouani H; Kuzu Y; Kuzu H; Brumeanu TD; Swiggard WJ; Steinman RM; Bona CA
    Eur J Immunol; 1993 Nov; 23(11):2746-50. PubMed ID: 8223850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.